John R. Mackey
Papers
1
Total Citations
64
H-Index
1
About
Dr. John R. Mackey is a leading oncologist and translational researcher whose work has fundamentally shaped the understanding and treatment of B-cell malignancies. His research centers on the molecular mechanisms driving lymphoma, with a particular focus on protein myristoylation—a critical lipid modification that anchors signaling proteins to cellular membranes. Dr. Mackey’s landmark 2020 study, “Targeting N-myristoylation for therapy of B-cell lymphomas,” which has garnered 64 citations, provided the first systematic investigation of N-myristoyltransferase (NMT) as a therapeutic vulnerability in lymphoma. By demonstrating that cancer cells exhibit elevated NMT expression and that its inhibition selectively disrupts oncogenic signaling, he established a novel paradigm for targeted therapy. This work has opened an entirely new avenue for drug development, moving beyond traditional chemotherapy toward precision medicine in hematologic cancers. Dr. Mackey’s contributions extend beyond the lab; he is a sought-after clinical trialist and has been instrumental in translating these basic discoveries into early-phase clinical studies. His research continues to inspire a generation of scientists exploring post-translational modifications as druggable targets in oncology.
Research Focus
Key Achievements
Top Papers
- 1Targeting N-myristoylation for therapy of B-cell lymphomas64 citations · 2020